Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Impaired Liver Function and Healthy Participants Matched for Age-, Gender-, and Weight

Inclusion criteria for all subjects: * Male and female White subjects 18 to ≤79 years of age, BMI between 18 and 34 kg/m\^2 * Women without childbearing potential or with childbearing potential but only if the pregnancy test is negative and are under highly effective contraception Inclusion criteria for subjects with liver cirrhosis: * Documented liver cirrhosis confirmed by histopathology, eg previous liver biopsy, laparoscopy, or ultrasound Hepatic impairment (Child Pugh A or B) * Stable liver disease Inclusion criteria for healthy subjects: \- Age- (+/-10 years), weight- (+/-10 kg body weight), and gender-matched to a subject with liver cirrhosis as far as possible Exclusion criteria for all subjects: * Febrile illness within 1 week before the start of the study * Hypersensitivity to riociguat and / or to inactive constituents * Smoking Exclusion criteria for subjects with liver cirrhosis: * Hemoglobin \<8 g/dL * Severe cerebrovascular or cardiac disorders, eg myocardial infarction less than 6 months prior to dosing, congestive heart failure of NYHA grade III or IV, severe arrhythmia requiring antiarrhythmic treatment * Evidence of hepatic encephalopathy related to chronic liver disease \> Grade II * Renal failure with a creatinine clearance \<40 mL/min * Resting heart rate in the awake subject below 45 BPM or above 100 BPM * Systolic blood pressure (SBP) below 100 mmHg or above 160 mmHg, Diastolic blood pressure (DBP) above 95 mmHg * Platelet count \<30 x 10\^9/L…